Jonas Alex Morales Saute

List of Publications by Year
in descending order

72	1,792	218677	302126
papers	citations	26 h-index	39 g-index

73	73	73	2782
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic yield of multi-gene panel for muscular dystrophies and other hereditary myopathies. Neurological Sciences, 2022, 43, 4473-4481.	1.9	4
2	Speech and swallowing characteristics in patients with facioscapulohumeral muscular dystrophy. Arquivos De Neuro-Psiquiatria, 2022, , .	0.8	0
3	Accuracy of muscle fasciculations for the diagnosis of later-onset spinal muscle atrophy. Neuromuscular Disorders, 2022, 32, 763-768.	0.6	2
4	Rapid-Onset Dystonia-Parkinsonism Phenotype Consistency for a Novel Variant of ATP1A3 in Patients Across 3 Global Populations. Neurology: Genetics, 2021, 7, e562.	1.9	2
5	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nature Medicine, 2021, 27, 1197-1204.	30.7	96
6	Genetic epidemiology of familial ALS in Brazil. Neurobiology of Aging, 2021, 102, 227.e1-227.e4.	3.1	12
7	Progression of Functional Gait in Hereditary Spastic Paraplegias. Cerebellum, 2021, , 1.	2.5	5
8	Juliano Moreira: the black Brazilian who greatly influenced the modern school of Neurology in Brazil. Arquivos De Neuro-Psiquiatria, 2021, 79, 650-653.	0.8	1
9	Clinical trials for genetic diseases in Latin America. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 381-387.	1.6	0
10	Evoked potentials as biomarkers of hereditary spastic paraplegias: A case-control study. PLoS ONE, 2021, 16, e0259397.	2.5	2
11	Clinical and molecular characterization of a large cohort of childhood onset hereditary spastic paraplegias. Scientific Reports, 2021, 11, 22248.	3.3	8
12	Cognitive profile of patients with facioscapulohumeral muscular dystrophy. Dementia E Neuropsychologia, 2021, 15, 541-547.	0.8	0
13	Diagnostic yield of targeted sequential and massive panel approaches for inherited neuropathies. Clinical Genetics, 2020, 98, 185-190.	2.0	13
14	Neurological Phenotypes Associated with AAAS-Related Disorders: Spastic Ataxia and Complex Spastic Paraplegia. Cerebellum, 2020, 19, 465-468.	2.5	1
15	Are Cognitive Changes in Hereditary Spastic Paraplegias Restricted to Complicated Forms?. Frontiers in Neurology, 2019, 10, 508.	2.4	13
16	Clinicogenetic lessons from 370 patients with autosomal recessive limbâ€girdle muscular dystrophy. Clinical Genetics, 2019, 96, 341-353.	2.0	38
17	State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change. Genetics and Molecular Biology, 2019, 42, 238-251.	1.3	6
18	Evidence-Based Consensus and Systematic Review on Reducing the Time to Diagnosis of Duchenne Muscular Dystrophy. Journal of Pediatrics, 2019, 204, 305-313.e14.	1.8	24

#	Article	IF	Citations
19	A systematic review and evidence-based guideline for diagnosis and treatment of Menkes disease. Molecular Genetics and Metabolism, 2019, 126, 6-13.	1.1	48
20	Dropped head syndrome as a manifestation of Charcotâ€“Marieâ€“Tooth disease type 4C. Neuromuscular Disorders, 2019, 29, 138-141.	0.6	5
21	Autonomic dysfunction in hereditary spastic paraplegia type 4. European Journal of Neurology, 2019, 26, 687-693.	3.3	2
22	Prevalence of oropharyngeal dysphagia in hereditary spastic paraplegias. Arquivos De Neuro-Psiquiatria, 2019, 77, 843-847.	0.8	3
23	Planning Future Clinical Trials for Machado-Joseph Disease. Advances in Experimental Medicine and Biology, 2018, 1049, 321-348.	1.6	12
24	Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. The Lancet Child and Adolescent Health, 2018, 2, 56-68.	5.6	32
25	Clinical aspects of hereditary spastic paraplegia 76 and novel CAPN1 mutations. Clinical Genetics, 2018, 94, 482-483.	2.0	8
26	Genetic profile of Brazilian patients with dystrophinopathies. Clinical Genetics, 2017, 92, 199-203.	2.0	13
27	A Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Mimics on Brain Magnetic Resonance Imaging in Myotonic Dystrophy Type I. JAMA Neurology, 2017, 74, 866.	9.0	1
28	Cancer in Machadoâ€“Joseph disease patientsâ€”low frequency as a cause of death. Cancer Genetics, 2017, 212-213, 19-23.	0.4	6
29	Letter re: Cathepsin Aâ€“related arteriopathy with strokes and leukoencephalopathy (CARASAL). Neurology, 2017, 88, 1776-1776.	1.1	1
30	Spinocerebellar ataxia type 10: common haplotype and disease progression rate in Peru and Brazil. European Journal of Neurology, 2017, 24, 892.	3.3	12
31	Clinical and molecular characterization of hereditary spastic paraplegias: A next-generation sequencing panel approach. Journal of the Neurological Sciences, 2017, 383, 18-25.	0.6	44
32	Challenges in quantifying ataxia in core and comorbid early onset ataxias. Developmental Medicine and Child Neurology, 2017, 59, 350-351.	2.1	0
33	Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. Brain, 2017, 140, 3112-3127.	7.6	87
34	Brazilian consensus on Duchenne muscular dystrophy. Part 1: diagnosis, steroid therapy and perspectives. Arquivos De Neuro-Psiquiatria, 2017, 75, 104-113.	0.8	16
35	Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machadoâ€“Joseph Disease. Frontiers in Neurology, 2017, 8, 485.	2.4	47
36	Autosomal recessive spastic ataxia of Charlevoix-Saguenay: a family report from South Brazil. Arquivos De Neuro-Psiquiatria, 2017, 75, 339-344.	0.8	6

#	Article	IF	Citations
37	Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome. Arquivos De Neuro-Psiquiatria, 2016, 74, 953-966.	0.8	11
38	MR Imaging in Spinocerebellar Ataxias: A Systematic Review. American Journal of Neuroradiology, 2016, 37, 1405-1412.	2.4	41
39	D<scp>NAJC</scp>6<scp>M</scp>utations <scp>A</scp>ssociated <scp>W</scp>ith <scp>E</scp>arlyâ€<scp>O</scp>nset <scp>P</scp>arkinson's <scp>D</scp>isease. Annals of Neurology, 2016, 79, 244-256.	5.3	148
40	Riluzole in patients with hereditary cerebellar ataxia. Lancet Neurology, The, 2016, 15, 788-789.	10.2	4
41	Nonâ€motor symptoms in patients with hereditary spastic paraplegia caused by SPG4 mutations. European Journal of Neurology, 2016, 23, 408-411.	3.3	20
42	Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence. Neurogenetics, 2016, 17, 107-113.	1.4	15
43	Spinocerebellar ataxia type 3/Machadoâ€"Joseph disease: segregation patterns and factors influencing instability of expanded <scp>CAG</scp> transmissions. Clinical Genetics, 2016, 90, 134-140.	2.0	36
44	Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. Journal of Neurology, 2016, 263, 818-820.	3.6	21
45	Cytokines in Machado Joseph Disease/Spinocerebellar Ataxia 3. Cerebellum, 2016, 15, 518-525.	2.5	27
46	Clinical Scales Predict Significant Videofluoroscopic Dysphagia in Machado Joseph Disease Patients. Movement Disorders Clinical Practice, 2015, 2, 260-266.	1.5	5
47	Infantile spinocerebellar ataxia type 7: Case report and a review of the literature. Journal of the Neurological Sciences, 2015, 354, 118-121.	0.6	11
48	Broad clinical and laboratory spectrum found in 9 Niemannâ€"Pick disease type C Southern Brazilian patients. Molecular Genetics and Metabolism, 2015, 114, S35.	1.1	0
49	Look carefully to the heels! A potentially treatable cause of spastic paraplegia. Journal of Inherited Metabolic Disease, 2015, 38, 363-364.	3.6	15
50	Machado Joseph disease: clinical and genetic aspects, and current treatment. Expert Opinion on Orphan Drugs, 2015, 3, 517-535.	0.8	41
51	Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial. Journal of the Neurological Sciences, 2015, 358, 72-76.	0.6	28
52	<scp>SPG4</scp>â€related hereditary spastic paraplegia: frequency and mutation spectrum in Brazil. Clinical Genetics, 2014, 86, 194-196.	2.0	10
53	Huntington disease and Huntington diseaseâ€like in a case series from Brazil. Clinical Genetics, 2014, 86, 373-377.	2.0	26
54	A randomized, phase 2 clinical trial of lithium carbonate in Machadoâ€Joseph disease. Movement Disorders, 2014, 29, 568-573.	3.9	65

#	Article	IF	Citations
55	Nonmotor and extracerebellar features in Machadoâ€Joseph disease: A review. Movement Disorders, 2013, 28, 1200-1208.	3.9	79
56	Body Mass Index is Inversely Correlated with the Expanded CAG Repeat Length in SCA3/MJD Patients. Cerebellum, 2012, 11, 771-774.	2.5	38
57	Ataxia Rating Scalesâ€"Psychometric Profiles, Natural History and Their Application in Clinical Trials. Cerebellum, 2012, 11, 488-504.	2.5	101
58	Effects of 3Âweeks GMP oral administration on glutamatergic parameters in mice neocortex. Purinergic Signalling, 2012, 8, 49-58.	2.2	3
59	Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: An open label clinical trial. Movement Disorders, 2011, 26, 358-359.	3.9	32
60	Serum insulinâ€like system alterations in patients with spinocerebellar ataxia type 3. Movement Disorders, 2011, 26, 731-735.	3.9	35
61	Progression Rate of Neurological Deficits in a 10-Year Cohort of SCA3 Patients. Cerebellum, 2010, 9, 419-428.	2.5	45
62	Depressive Mood is Associated with Ataxic and Non-Ataxic Neurological Dysfunction in SCA3 Patients. Cerebellum, 2010, 9, 603-605.	2.5	17
63	Effects of Depressive-Like Behavior of Rats on Brain Glutamate Uptake. Neurochemical Research, 2010, 35, 1164-1171.	3.3	41
64	Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Brazilian Journal of Medical and Biological Research, 2010, 43, 537-542.	1.5	31
65	The role of lithium in ALS remains unknown. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 574-574.	2.1	4
66	A Prospective Study of SCA3 Gait Ataxia Described through a Markovian Method. Neuroepidemiology, 2010, 34, 163-170.	2.3	5
67	Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in ParkinsonÂ´s disease. Metabolic Brain Disease, 2009, 24, 257-269.	2.9	61
68	Interleukin-6 Serum Levels in Patients with Parkinsonâ€™s Disease. Neurochemical Research, 2009, 34, 1401-1404.	3.3	75
69	A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). European Journal of Neurology, 2008, 15, 371-376.	3.3	70
70	When ataxia is not just ataxia. Nature Clinical Practice Neurology, 2007, 3, E2-E2.	2.5	4
71	Amnesic effect of GMP depends on its conversion to guanosine. Neurobiology of Learning and Memory, 2006, 85, 206-212.	1.9	32
72	Spinocerebellar ataxias in 114 Brazilian families: clinical and molecular findings. Clinical Genetics, 2006, 70, 173-176.	2.0	24